Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice

Clinical and Vaccine Immunology

Volumn 15, Issue 4, 2008, Pages 668-674

  Badiee, Ali ^a,b   Jaafari, Mahmoud R ^a   Samiei, Afshin ^a   Soroush, Dina ^a   Khamesipour, Ali ^b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; LIPOSOME; PHOSPHATE BUFFERED SALINE; RECOMBINANT PROTEIN; RECOMBINANT STRESS INDUCIBLE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG POTENCY; ENCAPSULATION; FEMALE; FOOT PAD; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SWELLING; TH1 CELL;

ANIMALS; ANTIBODIES, PROTOZOAN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HEAT-SHOCK PROTEINS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LIPOSOMES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS; SPLEEN; TH1 CELLS;

EID: 47049085330     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00413-07     Document Type: Article

References (47)

1. Ahmad-Nejad, P., H. Hacker, M. Rutz, S. Bauer, R. M. Vabulas, and H. Wagner. 2002. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32:1958-1968.
2. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124:783-801.
3. Alving, C. R. 1995. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann. N. Y. Acad. Sci. 754:143-152.
4. Campos-Neto, A., R. Porrozzi, K. Greeson, R. N. Coler, J. R. Webb, Y. A. W. Seiky, S. G. Reed, and G. Grimaldi. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:4103-4108.
5. Chu, R. S., D. Askew, and C. V. Harding. 2000. CpG DNA switches on Th1 immunity and modulates antigen-presenting cell function. Curr. Top. Microbiol. Immunol. 247:199-210.
6. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623-1631.
7. Coffman, R. L., D. A. Lebman, and P. Rothman. 1993. Mechanism and regulation of immunoglobulin isotype switching. Adv. Immunol. 54:229-270.
8. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
9. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccination consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225.
10. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
11. De Oliveira, M. C., V. Boutet, E. Fattal, D. Boquet, J. M. Grognet, P. Couvreur, and J. R. Deverre. 2000. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sci. 67:1625-1637.
12. Gradoni, L., F. V. Manzillo, A. Pagano, D. Piantedosi, R. De Luna, M. Gramiccia, A. Scalone, T. Di Muccio, and G. Oliva. 2005. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23:5245-5251.
13. Gregoriadis, G. 1990. Immunological adjuvant: a role for liposomes. Immunol. Today 11:89-97.
14. Jaafari, M. R., A. Badiee, A. Khamesipour, A. Samiei, D. Soroush, M. T. Kheiri, F. Barkhordari, W. R. McMasterd, and F. Mahboudi. 2007. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25:6107-6117.
15. Jaafari, M. R., A. Ghafarian, A. Farrokh-Gisour, A. Samiei, M. T. Kheiri, F. Mahboudi, F. Barkhordari, A. Khamesipour, and W. R. McMaster. 2006. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24:5708-5717.
16. Jiao, X., R. Y. Wang, Q. Qiu, H. J. Alter, and J. W. Shih. 2004. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J. Gen. Virol. 85:1545-1553.
17. Khamesipour, A., S. Rafati, N. Davoudi, F. Maboudi, and F. Modabber. 2006. Leishmaniasis vaccine candidates for development: a global overview. Indian J. Med. Res. 123:423-438.
18. Khamesipour, A., Y. Dowlati, A. Asilian, R. Hashemi-Fesharki, A. Javadi, S. Noazin, and F. Modabber. 2005. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 23:3642-3648.
19. Kirby, C., and G. Gregoriadis. 1984. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 2:979-984.
20. Klinman, D. M. 2004. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin. Biol. Ther. 4:937-946.
21. Klinman, D. M., D. Currie, I. Gurse, and D. Verthelyi. 2004. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199:201-216.
22. Krieg, A. M. 2002. CpG motif in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
23. Li, W. M., W. H. Dragowska, M. B. Bally, and M. P. Schutze-Redelmeier. 2003. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21:3319-3329.
24. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
25. Mauel, J. 2002. Vaccination against Leishmania infections. Curr. Drug Targets Immune Endocr. Metab. Disord. 2:201-226.
26. Mazumdar, T., K. Anam, and N. Ali. 2005. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J. Parasitol. 91:269-274.
27. Melby, P. C. 2002. Vaccination against cutaneous leishmaniasis. Curr. Status Am. J. Clin. Dermatol. 3:557-570.
28. Mendez, S., S. Gurunathan, S. Kamhawi, Y. Belkaid, M. A. Moga, Y. A. Skeiky, A. Campos-Neto, S. Reed, R. A. Seder, and D. Sacks. 2001. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166:5122-5128.
29. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89:83-88.
30. Mutwiri, G. K., A. K. Nichani, S. Babiuk, and L. A. Babiuk. 2004. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control. Release 97:1-17.
31. O'Hagan, D. T., M. L. MacKichan, and M. Singh. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18:69-85.
32. O'Hagan, D. T., and M. Singh. 2003. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2:269-283.
33. Oussoren, C., and G. Storm. 2001. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. 50:143-156.
34. Park, A. Y., and P. Scott. 2001. IL-12: keeping cell-mediated immunity alive. Scand. J. Immunol. 53:529-532.
35. + T cell responses and protection against Leishmania major infection. J. Exp. Med. 195:1565-1573.
36. Sacks, D., and N. Noben-Trauth. 2002. The immunology of susceptibility and resistance to Leishmania major in mice. Nat. Rev. Immunol. 2:845-858.
37. Skeiky, Y. A., R. N. Coler, M. Branon, E. Stromberg, K. Greeson, R. T. Crane, A. Campos-Neto, and S. G. Reed. 2002. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (leish-111f) formulated in MPL adjuvant. Vaccine 20:3292-3303.
38. Stacey, K. J., and J. M. Blackwell. 1999. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67:3719-3726.
39. Suzuki, Y., D. Wakita, K. Chamoto, Y. Narita, T. Tsuji, T. Takeshima, H. Gyobu, Y. Kawarada, S. Kondo, S. Akira, H. Katoh, H. Ikeda, and T. Nishimura. 2004. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 64:8754-8760.
40. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J. Immunol. 126:1614-1619.
41. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555.
42. Walker, P. S., T. Scharton-Kersten, A. M. Krieg, L. Love-Homan, E. D. Rowton, M. C. Udey, and J. C. Vogel. 1999. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc. Natl. Acad. Sci. USA 96:6970-6975.
43. Webb, J. R., W. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.
44. Weeratna, R. D., C. L. Brazolot Millan, M. J. McCluskie, and H. L. Davis. 2001. CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol. 32: 65-71.
45. World Health Organization. 2004. Leishmaniasis - disease information. World Health Organization, Geneva, Switzerland. http://www.who.int/tdr/diseases/leish/diseaseinfo.htm.
46. Yamakami, K., S. Akao, M. Sato, Y. Nitta, J. Miyazaki, and T. Tadakuma. 2001. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol. Int. 50:81-91.
47. Zhang, Y. M., M. Rusckowski, N. Liu, C. Liu, and D. J. Hnatowich. 2001. Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother. Radiopharm. 16:411-419.